10.12.2024 16:44:29
|
Arvinas, Pfizer Report Positive Data From Phase 1b Study Of Vepdegestrant Combination Therapy
(RTTNews) - Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE), Tuesday announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib in patients with locally advanced or metastatic estrogen receptor positive/human epidermal growth factor receptor 2 negative breast cancer.
The findings revealed that the combination of Aabemaciclib 150 mg twice daily with the recommended Phase 3 monotherapy dose of 200 mg of Vepdegestrant once daily was safe and well-tolerated in the participants. Moreover, it showed no significant drug-drug interaction, and no clinically meaningful effect on Abemaciclib exposure.
The companies added that the combination therapy demonstrated a clinical benefit rate of 62.5 percent, and overall response rate of 26.7 percent in patients previously treated with a CDK4/6 inhibitor.
Currently, Arvinas's stock is falling 1.75 percent, to $24.64 on the Nasdaq, while Pfizer's stock is trading at $25.81, down 1.13 percent on the New York Stock Exchange.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Arvinas Inc Registered Shsmehr Nachrichten
29.10.24 |
Ausblick: Arvinas legt Quartalsergebnis vor (finanzen.net) |
Analysen zu Arvinas Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Arvinas Inc Registered Shs | 22,54 | -8,34% | |
Pfizer Inc. | 24,05 | -1,05% |